JP2019504029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504029A5 JP2019504029A5 JP2018532723A JP2018532723A JP2019504029A5 JP 2019504029 A5 JP2019504029 A5 JP 2019504029A5 JP 2018532723 A JP2018532723 A JP 2018532723A JP 2018532723 A JP2018532723 A JP 2018532723A JP 2019504029 A5 JP2019504029 A5 JP 2019504029A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- tumor
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 9
- 210000000066 myeloid cell Anatomy 0.000 claims 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 6
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000005166 vasculature Anatomy 0.000 claims 2
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100034622 Complement factor B Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000710032 Homo sapiens Complement factor B Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 1
- 101000829761 Homo sapiens N-arachidonyl glycine receptor Proteins 0.000 claims 1
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims 1
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 claims 1
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims 1
- 102100035304 Lymphotactin Human genes 0.000 claims 1
- 102100023414 N-arachidonyl glycine receptor Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 1
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 claims 1
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270835P | 2015-12-22 | 2015-12-22 | |
| US62/270,835 | 2015-12-22 | ||
| US201662350224P | 2016-06-15 | 2016-06-15 | |
| US62/350,224 | 2016-06-15 | ||
| US201662399149P | 2016-09-23 | 2016-09-23 | |
| US62/399,149 | 2016-09-23 | ||
| PCT/US2016/068184 WO2017112838A1 (en) | 2015-12-22 | 2016-12-22 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504029A JP2019504029A (ja) | 2019-02-14 |
| JP2019504029A5 true JP2019504029A5 (https=) | 2020-02-06 |
Family
ID=59091176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532723A Pending JP2019504029A (ja) | 2015-12-22 | 2016-12-22 | クラスｉｉａ ｈｄａｃ阻害剤の使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200268720A1 (https=) |
| EP (1) | EP3393458A4 (https=) |
| JP (1) | JP2019504029A (https=) |
| WO (1) | WO2017112838A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| KR102237527B1 (ko) * | 2017-08-31 | 2021-04-07 | 차의과학대학교 산학협력단 | 성숙 수지상 세포 검출용 바이오마커 및 이의 용도 |
| WO2020202005A1 (en) * | 2019-04-02 | 2020-10-08 | Inxmed (Shanghai) Co., Ltd. | Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors |
| CN117693363A (zh) * | 2021-07-27 | 2024-03-12 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| CN115778950B (zh) * | 2022-11-23 | 2024-01-26 | 山西医科大学第二医院 | 组蛋白去乙酰化酶抑制剂tmp195在制备促进成骨形成药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849589A (en) * | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
| WO2010115115A1 (en) * | 2009-04-03 | 2010-10-07 | Inserm ( Institut National De La Sante Et De La Recherche) | Dendritic cell-boosted humanized immune system mice |
| WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| AU2012212323A1 (en) * | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
-
2016
- 2016-12-22 US US16/063,760 patent/US20200268720A1/en not_active Abandoned
- 2016-12-22 JP JP2018532723A patent/JP2019504029A/ja active Pending
- 2016-12-22 WO PCT/US2016/068184 patent/WO2017112838A1/en not_active Ceased
- 2016-12-22 EP EP16880073.8A patent/EP3393458A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504029A5 (https=) | ||
| Lee et al. | CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| WO2016109546A3 (en) | Methods and compositions for prognosis and treatment of cancers | |
| WO2018026819A3 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| EA201891092A1 (ru) | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| WO2015161276A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| MX2017007272A (es) | Metodos y composiciones para tratar cancer. | |
| MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2016531927A5 (https=) | ||
| PH12013500990A1 (en) | Neutralizing anti-ccl20 antibodies | |
| JP2017014254A5 (https=) | ||
| HK1249469A1 (zh) | 用RORγ抑制剂治疗癌症的方法 | |
| PH12015502090A1 (en) | Pan-elr+cxc chemokine antibodies | |
| EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
| EA201891601A1 (ru) | Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей | |
| NZ774030A (en) | Anti-human cd45rc antibodies and uses thereof |